🚀 VC round data is live in beta, check it out!
Sai Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sai Life Sciences and similar public comparables like ST Pharm, Bora Pharmaceuticals, Jiuzhou Pharmaceutical, Fagron and more.
Sai Life Sciences Overview
About Sai Life Sciences
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
Founded
1999
HQ
Employees
3.4K
Website
Financials (LTM)
EV
$2B
Sai Life Sciences Financials
Sai Life Sciences reported last 12-month revenue of $238M and EBITDA of $68M.
In the same LTM period, Sai Life Sciences generated $175M in gross profit, $68M in EBITDA, and $38M in net income.
Revenue (LTM)
Sai Life Sciences P&L
In the most recent fiscal year, Sai Life Sciences reported revenue of $199M and EBITDA of $48M.
Sai Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $238M | XXX | $199M | XXX | XXX | XXX |
| Gross Profit | $175M | XXX | $66M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $68M | XXX | $48M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $38M | XXX | $20M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sai Life Sciences Stock Performance
Sai Life Sciences has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Sai Life Sciences' stock price is $9.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.9% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSai Life Sciences Valuation Multiples
Sai Life Sciences trades at 8.8x EV/Revenue multiple, and 30.9x EV/EBITDA.
EV / Revenue (LTM)
Sai Life Sciences Financial Valuation Multiples
As of March 21, 2026, Sai Life Sciences has market cap of $2B and EV of $2B.
Equity research analysts estimate Sai Life Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sai Life Sciences has a P/E ratio of 55.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 8.8x | XXX | 10.6x | XXX | XXX | XXX |
| EV/EBITDA | 30.9x | XXX | 44.2x | XXX | XXX | XXX |
| EV/EBIT | 42.9x | XXX | 67.1x | XXX | XXX | XXX |
| EV/Gross Profit | 12.0x | XXX | 31.7x | XXX | XXX | XXX |
| P/E | 55.7x | XXX | 105.1x | XXX | XXX | XXX |
| EV/FCF | (56.1x) | XXX | (354.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sai Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sai Life Sciences Margins & Growth Rates
Sai Life Sciences' revenue in the last 12 month grew by 19%.
Sai Life Sciences' revenue per employee in the last FY averaged $0.1M.
Sai Life Sciences' rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sai Life Sciences' rule of X is 75% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sai Life Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 44% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 47% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 75% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sai Life Sciences Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Bora Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiuzhou Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Fagron | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sai Life Sciences M&A Activity
Sai Life Sciences acquired XXX companies to date.
Last acquisition by Sai Life Sciences was on XXXXXXXX, XXXXX. Sai Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sai Life Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSai Life Sciences Investment Activity
Sai Life Sciences invested in XXX companies to date.
Sai Life Sciences made its latest investment on XXXXXXXX, XXXXX. Sai Life Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sai Life Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sai Life Sciences
| When was Sai Life Sciences founded? | Sai Life Sciences was founded in 1999. |
| Where is Sai Life Sciences headquartered? | Sai Life Sciences is headquartered in India. |
| How many employees does Sai Life Sciences have? | As of today, Sai Life Sciences has over 3K employees. |
| Who is the CEO of Sai Life Sciences? | Sai Life Sciences' CEO is Krishnam Raju Kanumur. |
| Is Sai Life Sciences publicly listed? | Yes, Sai Life Sciences is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Sai Life Sciences? | Sai Life Sciences trades under SAILIFE ticker. |
| When did Sai Life Sciences go public? | Sai Life Sciences went public in 2024. |
| Who are competitors of Sai Life Sciences? | Sai Life Sciences main competitors are ST Pharm, Bora Pharmaceuticals, Jiuzhou Pharmaceutical, Fagron. |
| What is the current market cap of Sai Life Sciences? | Sai Life Sciences' current market cap is $2B. |
| What is the current revenue of Sai Life Sciences? | Sai Life Sciences' last 12 months revenue is $238M. |
| What is the current revenue growth of Sai Life Sciences? | Sai Life Sciences revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Sai Life Sciences? | Current revenue multiple of Sai Life Sciences is 8.8x. |
| Is Sai Life Sciences profitable? | Yes, Sai Life Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sai Life Sciences? | Sai Life Sciences' last 12 months EBITDA is $68M. |
| What is Sai Life Sciences' EBITDA margin? | Sai Life Sciences' last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Sai Life Sciences? | Current EBITDA multiple of Sai Life Sciences is 30.9x. |
| What is the current FCF of Sai Life Sciences? | Sai Life Sciences' last 12 months FCF is ($38M). |
| What is Sai Life Sciences' FCF margin? | Sai Life Sciences' last 12 months FCF margin is (16%). |
| What is the current EV/FCF multiple of Sai Life Sciences? | Current FCF multiple of Sai Life Sciences is (56.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.